In this edition of the Huntington's Disease Clinical Trials Corner we expand on the HD-DBS and on the TRIHEP3 trials, and we list all currently registered and ongoing clinical trials in Huntington's disease.
INTRODUCTION
The Huntington's Disease Clinical Trials Corner is a regular section devoted to highlighting ongoing and recently completed clinical trials in Huntington's disease (HD) . Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner are listed in Table 1 .
In this edition, we highlight the HD-DBS trial (NC T02535884) (1) , and the TRIHEP3 trial (NCT0245 3061) (2) . We tabulate all currently registered and ongoing clinical trials in Tables 2 to 4 . For further details on the methodology used, please refer to the first edition of Huntington's Disease Clinical Trials Corner (3) .
If you would like to draw attention to specific trials, please feel free to email us at: f.rodrigues@ucl.ac.uk and e.wild@ucl.ac.uk.
In addition to the above, the published report of the IONIS-HTT Rx trial (NCT02519036) is worthy of mention. The paper reports that monthly intrathecal IONIS-HTT Rx /RG6042 -an antisense oligonucleotide that signals wild-type and mutant huntingtin pre-mRNA to be degraded by RNase H1 -was safe and well-tolerated, and produced dosedependent reductions in cerebrospinal fluid mutant huntingtin in early HD patients (4) . This is an interesting signal but caution should be exercised as to whether this reduction translates into a clinically significant benefit for people with HD. Further investigation into the effects of this drug are expected from the currently ongoing phase 3 GENERATION-HD1 trial (NCT03761849) (5) and associated studies (6) (7) (8) (9) (10) . These studies will help us better characterize the safety profile of this compound, define the most efficient posology, and understand if it is associated with a clinically relevant benefit, and towards which disease domain.
ONGOING CLINICAL TRIALS
A list of all ongoing clinical trials is given in Tables 2-4 .
HD-DBS (NCT02535884)

Study title
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) (HD-DBS)(1). 
Intervention
DBS of the GP (11) with Medtronic ACTIVA® PC neurostimulator (Model 37601).
Description
The HD-DBS trial, sponsored by Heinrich-Heine University, aims to evaluate the efficacy and safety of pallidal DBS in adults (18 or more years of age) with manifest HD (i.e. clinically symptomatic and genetically confirmed [CAG ≥36]) and moderate disease stage (defined by the investigators as an Unified Huntington's Disease Rating Scale [UHDRS] total motor score [TMS] ≥30), chorea (UHDRS chorea score ≥10) and a Mattis Dementia Rating Scale ≥120, comparing with sham stimulation, for motor function.
People with juvenile or predominantly bradykinetic forms of the disease, postural instability, unstable medication in the 6 weeks previous to inclusion, unstable medical or psychiatric comorbidities, coagulopathies and/or increased risk of haemorrhage, implanted pacemaker or defibrillator, pregnant or breast-feeding are not eligible for this study.
This trial is an international, multi-centre, randomized, sham-controlled, double-blind, parallel study. It has 2 study arms: the stimulation group, where participants have stimulation turned on immediately after implantation of the stimulator; and the sham stimulation group, where participants will have a stimulator implanted but it will not be switched on. The study lasts 12 weeks, and after that period all participants' stimulators will be turned on.
The trial has already started recruitment, and has a recruitment target of 50 participants, over 4 countries (Austria, France, Germany and Switzerland) and 12 sites.
The primary outcome is the UHDRS TMS at 12 weeks, measured as the difference in the mean change from baseline between the stimulation arm and the sham-stimulation arm. The secondary outcomes include the UHDRS chorea score and the bradykinesia items, the Burke-Fahn-Marsden Dystonia Rating Scale, the Q-Motor choreomotography task, the Mattis Dementia Rating Scale, the Verbal Fluency Test, the Symbol Digits Modalities Test, the Stroop Test, the Hospital Anxiety and Depression Scales and the Snaith Irritability Scale, the Problem Behaviours Assessment Short Form, the Short Form 36 Health Survey, the Clinical Global Impression Scale, and safety.
Sponsors/funders
Heinrich-Heine University, KKS Netzwerk, Medtronic, the George Huntington Institute, EHDN and CHDI Foundation.
Comments
DBS is a relatively well-studied intervention for some manifestations of Parkinson's disease, tremor and dystonia. DBS involves the surgical implantation of electrical electrodes in the deep brain structures, connected via a wire to an implantable pulse generator (i.e. stimulator) usually positioned subcutaneously in the pectoral region. Although the precise mechanisms of action are still not completely understood, this intervention is aimed at interrupting certain neuronal circuits.
In Parkinson's disease DBS is frequently used to minimize levodopa-induced dyskinesia, which has a similar phenomenology to chorea in HD, but a different aetiology. This is accomplished by bet- ter controlling the cardinal features of PD, hence reducing the levodopa dose equivalents. There is still uncertainty about whether there is a direct effect of DBS over dyskinesia. In HD, chorea is thought to be caused by the loss of striatal projections to the indirect basal ganglia pathway and consequent thalamic overactivity (11) , and although there is a shortage of good-quality evidence, some pilot studies have shown interesting preliminary results when manipulating these circuits with DBS in HD (12, 13) .
The scarcity of data so far accumulated precludes drawing conclusions on the safety and efficacy profile of this intervention in HD, but it seems sensible to assume that this population may be susceptible to the same intervention-related adverse events as other tested populations. Disease-specific side effects may be more difficult to predict.
Only large well-controlled prospective controlled studies will allow us to fully understand the efficacy and safety profile of DBS in HD.
TRIHEP3 (NCT02453061)
Study title
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (TRIHEP3) (2) .
Intervention
Triheptanoin oil 1 g/kg/day (14) .
Description
The TRIHEP3 trial, sponsored by the Institut National de la Santé et de la Recherche Médicale and Ultragenyx Pharmaceutical Inc., aims to evaluate the effects of daily triheptanoin in adults (≥18 years of age) with genetically confirmed manifest HD (i.e. UHDRS TMS between 5 and 40), compared with daily safflower oil. People with a BMI <18 or >30, hypersensitivity to triheptanoin, major co-morbidities, history of severe head injury, pregnant or breastfeeding, or on tetrabenazine are not eligible.
TRIHEP3 is an international, multi-centre, randomized, double-blind, controlled, parallel phase 2 trial. It has 2 study arms: the active group, where participants receive triheptanoin oil 1 g/kg/day for 12 months; and the comparator group, where participants receive safflower oil 1 g/kg/day for 6 months and triheptanoin oil 1 g/kg/day for the following 6 months.
The study lasts 12 months, the first half over double-blinded conditions, and the second half as an open-label extension. Recruitment is currently closed and the study is being performed at one centre in France and one centre in the Netherlands. One hundred participants were recruited.
The primary outcomes are pharmacodynamics neuroimaging markers at 3 and 6 months -31 P-MRS and volumetric MRI. Secondary outcomes include the UHDRS, comprising the motor, functional and cognitive components, the Problem Behaviours Assessment Short Form, the Short Form 36 Health Survey, adverse events, tolerance and other neuroimaging biomarkers.
Sponsors/funders
Institut National de la Santé et de la Recherche Médicale and Ultragenyx Pharmaceutical Inc.
Comments Albeit with a low success rate (15) , several dietary nutrients with possible effects over metabolic processes have been tested in HD over the years, including d-␣-tocopherol (16) , idebenone (17), coenzyme Q10 (18), ethyl-eicosapentaenoate (19) (20) (21) , and creatine (22) (23) (24) .
Triheptanoin is an odd-chain triglyceride with anaplerotic properties (i.e. it replenishes biochemical cycles with intermediate metabolites), providing the Krebs cycle with both acetyl-CoA and propionyl-CoA. So far, triheptanoin has been tested for several disorders of the brain metabolism, including pyruvate decarboxylase deficiency, and GLUT1 deficiency where a significant symptomatic effect was demonstrated in a small open-label study (25) .
In HD, several lines of evidence support the existence of a dysfunction of the energy metabolism, including the Krebs cycle, oxidative phosphorylation and glycolysis. Two small open-label studies in HD showed that triheptanoin may have the potential to bring peripheral (26) and central nervous system metabolic biomarkers (27) to levels observed in healthy controls. They also anticipate triheptanoin to be well tolerated (26, 27) , and overall the cumulative evidence suggests a good safety profile for doses between 1 to 2.5 g/kg/day (14) .
The TRIHEP3 trial will be completed by the end of 2019 and the results are expected in mid-2020.
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